Daily Bio News Summary — 2026-08-25: FDA Activity Surges With Multiple Approvals and Designations

Today’s Harvest: 49 Articles From 8 Sources

Tuesday’s biopharma news cycle delivered a heavy FDA-centric batch: 49 articles drawn from PR Newswire FDA (14), Fierce Pharma (8), STAT News (7), BioSpace (7), BioPharma Dive (6), Fierce Biotech (4), MedCity News (2), and FDA Newsroom (1). The dominant themes are regulatory actions, deal-making, and clinical pipeline developments.

FDA Approvals and Authorizations

The FDA was unusually active today. Johnson & Johnson’s Imaavy (nipocalimab) received approval as the first-ever treatment for warm autoimmune hemolytic anemia, a rare blood disorder — covered by both Fierce Pharma and MedCity News. Jazz Pharmaceuticals secured an FDA nod for Ziihera in first-line HER2-positive gastric cancer, combining it with tislelizumab and chemotherapy. Masimo received 510(k) clearance for its Root monitor with LiDCO integration, and Abbott gained authorization for the world’s first dual glucose-ketone continuous sensing system — a meaningful advance for diabetes management.

On the designation front, Cellenkos received FDA Fast Track for CK0803 in ALS, and Mahzi Therapeutics earned Rare Pediatric Disease Designation for its gene therapy candidate MZ-1866.

Capricor’s DMD Rollercoaster

Capricor Therapeutics dominated the clinical-regulatory narrative with three separate articles: the FDA extended its review of the company’s Duchenne muscular dystrophy cell therapy by three months, giving the company a reprieve after earlier setbacks. CEO comments sparked a share price spike, while Cytokinetics filed suit against Bristol Myers Squibb in a separate matter. The Capricor story illustrates the volatility of cell therapy regulatory paths.

Deal Activity: Big Checks Across Borders

McKesson is acquiring a Maryland-based CRO for $2.25 billion, expanding its clinical services footprint. Metsera’s duo powered a $1.5 billion inflammatory disease deal through its Sentivera subsidiary. China’s Haisco formed an immunology biotech with up to $1.5 billion from American VCs, signaling continued cross-border capital flows despite geopolitical tensions. Roche gained rights to Hanmi’s obesity drug that reduces fat while preserving muscle — a differentiated mechanism in the increasingly crowded weight-loss space.

Pipeline Moves and Misses

Bausch + Lomb advanced its dry eye combo to Phase 3 despite a mid-stage miss, a bet on clinical persistence. AstraZeneca scored in lung cancer while Sandoz inked a China deal. EyePoint Pharmaceuticals plummeted on pivotal data for its lead drug. Slate and Fulcrum agreed to combine in a reverse merger. Bristol Myers won what BioPharma Dive called a “milestone” FDA approval for a myeloma drug acquired from Celgene.

What This Batch Is NOT Telling Us

Today’s harvest is notably light on AI-bio coverage, IPO activity (though BioSpace flagged biotech IPOs approaching “escape velocity”), and European regulatory news. The congressional commentary on China’s biotech strategy from Fierce Biotech hints at policy undercurrents but stays factual rather than opinion-driven.

Reading Order

For readers with limited time, prioritize:

1. J&J’s Imaavy approval — first-ever treatment for a rare anemia (Fierce Pharma, MedCity News)
2. McKesson’s $2.5B CRO acquisition — signals consolidation in clinical services (Fierce Pharma)
3. Capricor’s FDA extension — cell therapy regulatory path remains uncertain (BioSpace, BioPharma Dive, Fierce Biotech)
4. Haisco’s $1.5B China immunology play — cross-border VC in biotech (BioSpace)
5. Roche-Hanmi obesity deal — differentiated mechanism in weight-loss race (MedCity News)

Sources

All articles sourced from public career pages and industry news outlets. Per-article source URLs available in src/content/news/ via the sourceUrl frontmatter field.